HPC
CRL icon

HM Payson & Co’s Charles River Laboratories CRL Stock Holding History

HM Payson & Co’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-203
Closed -$30.6K – 1006
2025
Q1 		$30.6K Buy
+203
New +$34K ﹤0.01% 726
2022
Q3 		– Sell
-37
Closed -$8K – 993
2022
Q2 		$8K Buy
+37
New +$9.04K ﹤0.01% 833
2022
Q1 		– Sell
-30
Closed -$11K – 1070
2021
Q4 		$11K Hold
30
– – ﹤0.01% 848
2021
Q3 		$12K Hold
30
– – ﹤0.01% 814
2021
Q2 		$11K Hold
30
– – ﹤0.01% 812
2021
Q1 		$9K Sell
30
-29
-49% -$8.06K ﹤0.01% 869
2020
Q4 		$15K Buy
59
+29
+97% +$6.91K ﹤0.01% 816
2020
Q3 		$7K Buy
+30
New +$6.23K ﹤0.01% 864

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

HM Payson & Co's CRL Position: Q2 2025 in Review

HM Payson & Co sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 203 shares — an estimated $30.6K sold.

HM Payson & Co first reported a position in CRL in Q3 2020 and held it in 8 quarters. The position peaked at $30.6K in Q1 2025. 518 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

  • HM Payson & Co reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
  • HM Payson & Co sold 203 Charles River Laboratories shares in Q2 2025, an estimated $30.6K.
  • HM Payson & Co first reported a position in Charles River Laboratories in Q3 2020 and held it in 8 quarters.
  • HM Payson & Co's Charles River Laboratories position peaked at $30.6K in Q1 2025.
  • 518 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on HM Payson & Co's 13F filing for Q2 2025, filed 17 Oct 2025.